MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Parkinson’s disease biomarkers in human olfactory cleft mucus

J. Morley, N. Cohen, S. Koganti, S. Wood, H. Wang (Philadelphia, USA)

Meeting: 2024 International Congress

Abstract Number: 343

Keywords: Olfactory dysfunction, Parkinson’s

Category: Parkinson's Disease: Non-Motor Symptoms

Objective: To investigate and identify biomarkers for PD from human olfactory cleft mucus

Background: Olfactory loss is an early symptom of PD, often preceding motor symptoms by years. However, hyposmia is not specific for PD, and the underlying triggers of olfactory loss at the molecular level are expected to vary among different causes. Based on this hypothesis, molecular biomarkers from olfactory tissue may be able to improve PD diagnosis at the earliest stages. Therefore, in this study we are collecting olfactory cleft mucus from PD patients and age-matched controls and using molecular biomarker assays to identify potential biomarkers for PD

Method: Subjects with a clinical diagnosis of PD and control subjects without parkinsonism or active sinonasal disease are recruited from the CMCVAMC PADRECC and ENT clinics. Olfactory mucus is collected by placing specialized sponges in the olfactory groove between the middle turbinate and superior nasal septum under direct endoscopic visualization. After 10 min in the nose, sponges are placed in microfuge tubes, centrifuged at 10,000 rpm for 2 min. Olfactory mucus is collected,  aliquoted, snap frozen on dry ice, and stored at -80°C for batch processing. Putative protein biomarkers will be measured using Luminex-based multiplex immunoassays

Results: We have recruited and collected olfactory mucus from 36 PD subjects and 12 controls (target 40 per group).  PD subjects are similar in age to controls (73.8±6.9 vs 68.3±10.3, p=0.11) but have worse olfactory performance (BSIT 5.0±2.4 vs 7.9±2.4, p=0.002).  Preliminary results from our prior proteomic analyses showed that the α-Syn to DJ-1 ratio in olfactory mucus is significantly increased in PD patients relative to age-matched controls (p=0.0009) and has a strong biomarker potential (AUC = 0.907). We will present results testing the α-Syn /DJ-1 ratio from samples in the full cohort as well as candidates derived from machine learning-based unbiased biomarker discovery approaches.

Conclusion: Non-invasive olfactory cleft mucus sampling potentially offers a rich source for targeted and unbiased discovery of PD biomarkers

To cite this abstract in AMA style:

J. Morley, N. Cohen, S. Koganti, S. Wood, H. Wang. Parkinson’s disease biomarkers in human olfactory cleft mucus [abstract]. Mov Disord. 2024; 39 (suppl 1). https://www.mdsabstracts.org/abstract/parkinsons-disease-biomarkers-in-human-olfactory-cleft-mucus/. Accessed June 15, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2024 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/parkinsons-disease-biomarkers-in-human-olfactory-cleft-mucus/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Patients with Essential Tremor Live Longer than their Relatives
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley